Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of Neuronal Markers, NFP and GFAP, in Malignant Astrocytoma

  • Hashemi, Forough (Department of Pathology, School of Medicine, Iran University of Medical Sciences) ;
  • Naderian, Majid (Department of Pathology, School of Medicine, Iran University of Medical Sciences) ;
  • Kadivar, Maryam (Department of Pathology, School of Medicine, Iran University of Medical Sciences) ;
  • Nilipour, Yalda (Mofid Hospital, Pediatric Pathology Research Center, Shahid Beheshti Medical University) ;
  • Gheytanchi, Elmira (Oncopathology Research Center, Iran University of Medical Sciences)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Immunohistochemical markers are considered as important factors in diagnosis of malignant astrocytomas. The aim of the current study was to investigate the frequency of the immunohistochemical markers neurofilament protein (NFP) and glial fibrillary acidic protein (GFAP) in malignant astrocytoma tumors in Firoozgar and Rasool-Akram hospitals from 2005 to 2010. Materials and Methods: In this cross-sectional study, immunohistochemical analysis of NFP and GFAP was performed on 79 tissue samples of patients with the diagnosis of anaplastic and glioblastoma multiform (GBM) astrocytomas. Results: The obtained results demonstrated that all patients were positive for GFAP and only 3.8% were positive for NFP. There was no significant association between these markers and clinical, demographic, and prognostic features of patients (p>0.05). Conclusions: NFP was expressed only in GBMs and not in anaplastic astrocytomas. It would be crucial to confirm the present findings in a larger number of tumors, especially in high grade gliomas.

Keywords

References

  1. Dash RC, Provenzale JM, McComb RD, et al (1999). Malignant supratentorial ganglioglioma (ganglion cell-giant cell glioblastoma): a case report and review of the literature. Arch Pathol Lab Med, 123, 342-5.
  2. Dehghani F, Maronde E, Schachenmayr W, Korf HW (2000). Neurofilament H immunoreaction in oligodendrogliomas as demonstrated by a new polyclonal antibody. Acta Neuropathol, 100, 122-30. https://doi.org/10.1007/s004010050003
  3. Doroudchi M, Ghanaat Pishe Z, Malekzadeh M, et al (2013). Elevated serum IL-17A but not IL-6 in glioma versus meningioma and schwannoma. Asian Pac J Cancer Prev, 14, 5225-30. https://doi.org/10.7314/APJCP.2013.14.9.5225
  4. Efird JT (2011). Epidemiology Of Glioma, Glioma - Exploring its Biology and Practical Relevance, Dr. Anirban Ghosh (Ed.), 1-23. ISBN: 978-953-307-379-8, InTech,
  5. Fiks T, Jesionek-Kupnicka D, Zakrzewski K, Polis L, Liberski PP (1999). Clinicopathological analysis of pilocytic astrocytomas and gangliogliomas in children. Folia Neuropathol, 37, 152-6.
  6. Fiks T, Jesionek-Kupnicka D, Zakrzewski K, Polis L, Liberski PP (2001). Clinico-pathological analysis of pilocytic astrocytomas and gangliogliomas. Pol J Pathol, 52, 47-51.
  7. Furnari FB, Fenton T, Bachoo RM, et al (2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev, 21, 2683-710. https://doi.org/10.1101/gad.1596707
  8. Gheytanchi E, Mehrazma M, Madjd Z (2014). Expression of Ki-67, p53 and VEGF in pediatric neuroblastoma. Asian Pac J Cancer Prev, 15, 3065-70. https://doi.org/10.7314/APJCP.2014.15.7.3065
  9. Gotow T (2000). Neurofilaments in health and disease. Med Electron Microsc, 33, 173-99. https://doi.org/10.1007/s007950000019
  10. Gould VE, Rorke LB, Jansson DS, et al (1990). Primitive neuroectodermal tumors of the central nervous system express neuroendocrine markers and may express all classes of intermediate filaments. Hum Pathol, 21, 245-52. https://doi.org/10.1016/0046-8177(90)90223-R
  11. Hayashi Y, Iwato M, Hasegawa M, et al (2001). Malignant transformation of a gangliocytoma/ganglioglioma into a glioblastoma multiforme: a molecular genetic analysis. Case report. J Neurosurg, 95, 138-42. https://doi.org/10.3171/jns.2001.95.1.0138
  12. Jay V, Squire J, Becker LE, Humphreys R (1994). Malignant transformation in a ganglioglioma with anaplastic neuronal and astrocytic components. Report of a case with flow cytometric and cytogenetic analysis. Cancer, 73, 2862-8. https://doi.org/10.1002/1097-0142(19940601)73:11<2862::AID-CNCR2820731133>3.0.CO;2-5
  13. Katsetos CD, Del Valle L, Geddes JF, et al (2001). Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med, 125, 613-24.
  14. Keymoosi H, Gheytanchi E, Asgari M, Shariftabrizi A, Madjd Z (2014). ALDH1 in Combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev, 15, 2013-20. https://doi.org/10.7314/APJCP.2014.15.5.2013
  15. Kleinert R (1991). Immunohistochemical characterization of primitive neuroectodermal tumors and their possible relationship to the stepwise ontogenetic development of the central nervous system. 1. Ontogenetic studies. Acta Neuropathol, 82, 502-7. https://doi.org/10.1007/BF00293385
  16. Kleinert R (1991). Immunohistochemical characterization of primitive neuroectodermal tumors and their possible relationship to the stepwise ontogenetic development of the central nervous system. 2. Tumor studies. Acta Neuropathol, 82, 508-15. https://doi.org/10.1007/BF00293386
  17. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
  18. Madjd Z, Karimi A, Molanae S, Asadi- Lari M (2011). BRCA1 protein expression level and CD44(+) phenotype in breast cancer patients. Cell J, 13, 155-62.
  19. Morrison CD, Prayson RA (2000). Immunohistochemistry in the diagnosis of neoplasms of the central nervous system. Semin Diagn Pathol, 17, 204-15.
  20. Ohgaki H, Kleihues P (2013). The definition of primary and secondary glioblastoma. Clin Cancer Res, 19, 764-72. https://doi.org/10.1158/1078-0432.CCR-12-3002
  21. Pallud J, Dezamis E, Audureau E et al (2012). Neuronal immunoexpression and a distinct subtype of adult primary supratentorial glioblastoma with a better prognosis. J Neurosurg, 117, 476-85. https://doi.org/10.3171/2012.5.JNS111670
  22. Powell SZ, Yachnis AT, Rorke LB, Rojiani AM, Eskin TA (1996). Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. Am J Surg Pathol, 20, 80-5. https://doi.org/10.1097/00000478-199601000-00009
  23. Restrepo A, Smith CA, Agnihotri S, et al (2011). Epigenetic regulation of glial fibrillary acidic protein by DNA methylation in human malignant gliomas. Neuro Oncol, 13, 42-50. https://doi.org/10.1093/neuonc/noq145
  24. Rooprai HK, Merzak A, Bullock P, Pilkington GJ(1997). Establishment and characterization of two paediatric brain tumour cell lines in vitro. Anticancer Res, 17, 4127-34.
  25. Rushing EJ, Sandberg GD, Horkayne-Szakaly I (2010). Highgrade astrocytomas show increased nestin and wilms's tumor gene (WT1) protein expression. Int J Surg Pathol, 18, 255-9. https://doi.org/10.1177/1066896909338596
  26. Sasaki A, Hirato J, Nakazato Y, Tamura M, Kadowaki H (1996). Recurrent anaplastic ganglioglioma: pathological characterization of tumor cells. Case report. J Neurosurg, 84, 1055-9. https://doi.org/10.3171/jns.1996.84.6.1055
  27. Sotoudeh K, Hashemi F, Madjd Z, et al (2012). The clinicopathologic association of c-MET overexpression in iranian gastric carcinomas; an immunohistochemical study of tissue microarrays. Diagn Pathol, 7, 1-17. https://doi.org/10.1186/1746-1596-7-1
  28. Varlet P, Soni D, Miquel C, et al (2004). New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery, 55, 1377-91
  29. Wacker MR, Cogen PH, Etzell JE, et al (1992). Diffuse leptomeningeal involvement by a ganglioglioma in a child. Case report. J Neurosurg, 77, 302-6. https://doi.org/10.3171/jns.1992.77.2.0302
  30. Wharton SB, Chan KK, Whittle IR (2002). Microtubuleassociated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci, 9, 165-9. https://doi.org/10.1054/jocn.2001.1055
  31. Wolf HK, Buslei R, Blumcke I, Wiestler OD, Pietsch T (1997). Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors. Acta Neuropathol, 94, 436-43. https://doi.org/10.1007/s004010050730
  32. Yan T, Skaftnesmo KO, Leiss L, et al (2011). Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide. BMC Cancer, 11, 1-11. https://doi.org/10.1186/1471-2407-11-1
  33. Zeybek U, Yaylım I, Ozkan NE, et al (2013). Cyclin D1 gene G870A variants and primary brain tumors. Asian Pac J Cancer Prev, 14, 4101-6. https://doi.org/10.7314/APJCP.2013.14.7.4101

Cited by

  1. Importance of GFAP isoform-specific analyses in astrocytoma pp.08941491, 2019, https://doi.org/10.1002/glia.23594